The most useful questions to ask before starting sermorelin cover the goal, medical history, lab tests, and what happens afterward. A clear answer connects each of those to a plan, including reasons to pause or choose something else.
Sermorelin signals the pituitary, a small gland at the base of the brain, to release growth hormone. That hormone is a chemical messenger involved in growth and tissue repair. Existing hormone problems and past treatment become part of the conversation. These ten questions describe what a provider reviews.
Questions to ask before starting sermorelin
1. What result are we discussing, and what supports it?
Why it matters: A higher hormone reading is different from better sleep, less body fat, or more strength.
Vittone's 1997 study in Metabolism followed 11 healthy older men for six weeks. Overnight growth-hormone release increased, but IGF-1, a blood marker of growth-hormone activity, did not. Weight and measured muscle and fat also stayed unchanged. Two of six strength measures improved. The study was small and lacked a parallel placebo group, meaning a comparison group receiving an inactive treatment.
Khorram's 1997 study in The Journal of Clinical Endocrinology & Metabolism used a modified hormone analogue, a related molecule with a changed building block. Those results belong to that molecule, not sermorelin.
A good answer: It names a specific goal and explains which sermorelin clinical trials actually measured it.
2. Does my pituitary or thyroid history change the review?
Why it matters: Sermorelin depends on the pituitary's ability to respond. Ireland's archived Geref diagnostic label, for a former test of pituitary function, also notes that untreated low thyroid function can affect the response.
A good answer: It explains how previous pituitary surgery, radiation, hormone diagnoses, and thyroid treatment affect whether sermorelin fits.
3. How does active cancer or a past cancer diagnosis affect the decision?
Why it matters: Adult study findings don't settle safety in people with cancer. Vitiello's 2006 trial in Neurobiology of Aging excluded people with personal or strong family histories of breast, prostate, or colon cancer. It enrolled 100 older adults; 89 completed six months.
A good answer: It addresses current disease, past treatment, and whether records or input from the cancer specialist are needed before a decision.
Health history, medicines, and sermorelin labs before starting
4. How do pregnancy, pregnancy plans, or breastfeeding affect the review?
Why it matters: The archived Irish Geref label rules out use during pregnancy and breastfeeding. That label concerns diagnostic use. It doesn't establish safety for ongoing compounded treatment, medicine prepared by a pharmacy for an individual prescription.
A good answer: It addresses current pregnancy, plans to conceive, and breastfeeding directly. It explains how those facts change the proposed plan rather than treating the old brand's history as reassurance.
5. Which medicines and past hormone products matter?
Why it matters: The Geref diagnostic label lists medicines that can change the hormone response, including insulin, steroid medicines, and some pain medicines. The intake also captures previous growth hormone, peptides, and products obtained without a prescription.
As of September 30, 2026, the day this article was written, a July 3 case report in Frontiers in Surgery highlights the value of that history. It describes swallowing trouble with neck bone spurs in someone reporting years of several hormone products, including sermorelin. The history was self-reported and included a neck injury. One case cannot show that sermorelin caused the problem.
A good answer: It reviews product names, timing, and symptoms without assuming that an old or unprescribed product is irrelevant. Any medication change has its own prescriber plan.
6. What will baseline IGF-1 and other tests tell us?
Why it matters: A starting IGF-1 result gives later tests something to compare against. It isn't a diagnosis by itself. The Endocrine Society's 2011 guidance says confirmation of adult growth-hormone deficiency usually requires stimulation testing, which measures the response to a medical trigger.
A good answer: It explains the age-adjusted lab range, whether thyroid or blood-sugar tests are relevant, and which findings would change the decision.
Safety, sport, and the prescription plan
7. Which reactions need a call, and which need emergency care?
Why it matters: Brief flushing or injection-site discomfort appears in the archived Geref label. Breathing trouble, throat or tongue swelling, or fainting can signal anaphylaxis, a life-threatening allergic reaction. Those symptoms require an immediate 911 call.
A good answer: It separates emergency symptoms from problems handled through follow-up. It identifies whom to contact and how reactions are reviewed before treatment continues.
8. Does tested sport change the plan?
Why it matters: A prescription and permission under sport rules are separate decisions.
As of September 30, 2026, the day this article was written, WADA, the World Anti-Doping Agency, has published its 2027 list. Its September 21 announcement sets January 1, 2027 as the effective date. The list names sermorelin under S2.2.4, prohibited both during and outside competition. The current 2026 list already names sermorelin in the same class.
A good answer: It identifies the applicable sport rules and the therapeutic use exemption process, formal permission for a qualifying medical need. A prescription alone doesn't grant that permission.
9. What does the prescription and follow-up plan say?
Why it matters: Promise lists an injectable formulation. The prescription needs to match the supplied vial, with the concentration, meaning the amount of medicine in each milliliter, explained. The prescribed amount, schedule, storage instructions, and missed-dose plan also need to be clear. Sermorelin dosing decisions belong to the prescriber.
The product's history also deserves a clear answer. Geref's approvals were withdrawn effective June 18, 2009, after the manufacturer requested withdrawal. FDA's March 4, 2013 notice says the products were not withdrawn for safety or effectiveness.
Compounded sermorelin is different from an FDA-approved product: the formulation offered here is not FDA-approved. Promise offers sermorelin by prescription, after a licensed provider reviews your request. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
A good answer: It gives a written schedule and follow-up date, with the original goal, repeat tests, and side effects reviewed together. It explains what would justify continuing, changing, or stopping treatment. A lab number alone isn't the whole assessment.
Cost, availability, and the next step
10. What is included in the cost, and are medical visits open?
Why it matters: Medication, intake, lab work, supplies, shipping, and follow-up may appear as separate charges. An email waitlist isn't a medical visit. Availability and the clinical decision are separate parts of the process.
A good answer: It explains the current quote, what it includes, possible recurring charges, and how cancellations work. It also makes clear whether the next step is an intake, an appointment, or a waitlist notification.
A visit can end with a request for records or tests before a decision. The useful answer identifies what's missing and who reviews it. If the evidence doesn't match the goal, that belongs in the discussion too. The plan is easier to understand when the reason for each step is clear.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
